摘要
阿德福韦 (adefovir)是新一代核苷类抗病毒药物 ,能够有效抑制逆转录病毒、嗜肝病毒和疱疹病毒等各种病毒的复制和表达。实验研究表明阿德福韦不仅对慢性乙型肝炎病毒有着显著的抑制作用 ,而且其对于拉米夫定等耐药的变异病毒株同样有效 ,是一种新型的核苷类抗病毒药 ,预期可望成为解决核苷类似物耐药问题的有效办法。在迄今为止的实验中 ,阿德福韦显示了良好的安全及有效性。本文主要对阿德福韦的药理作用机制、临床应用进展等作一综述。
ABSTRACT Adefovir is an acyclic nucleotide antivivotic with activity against an broad range of viruses. It has potent activity of suppression virus'(retroviruses, herpesviruses and hepadnaviruses) duplication and expression. It is active against wild-type HBV and lamivudine-resistant HBV. It is a new nucleotide antivirotic which can effectively solve the tolerance of HBV. To date, adefovir displays a good safety and effectiveness in the clinical study and has no drug resistance to be found. The mechanism of pharmacology and recent advance in clinical trials of adefovir are reviewed in this paper.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2004年第6期373-377,共5页
Chinese Journal of New Drugs and Clinical Remedies
